Immunotherapy in all aspects.

Subcutaneous and Sublingual Immunotherapy in Allergic Asthma in Children. Front Pediatr (2017) 0.75

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy (2008) 12.35

Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol (2001) 7.27

Clinical guidelines: developing guidelines. BMJ (1999) 6.01

Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med (1999) 5.46

Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol (1998) 3.27

Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol (2006) 3.08

Relation of CD4+CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. Lancet (2004) 3.05

Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev (2007) 2.77

Standards for practical allergen-specific immunotherapy. Allergy (2006) 2.70

IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol (2003) 2.62

Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol (2004) 2.40

Side-effects of allergen-specific immunotherapy: a prospective multi-centre study. Clin Exp Allergy (2006) 2.36

Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J Allergy Clin Immunol (2004) 2.18

Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol (2004) 2.15

Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol (2010) 2.11

Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy (2007) 2.10

Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy (2003) 2.08

Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method. Allergy (2006) 1.97

Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol (2003) 1.94

Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol (2011) 1.84

Increases in IL-12 messenger RNA+ cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy. J Allergy Clin Immunol (1997) 1.73

Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial. Clin Exp Allergy (2010) 1.72

The safety of sublingual-swallow immunotherapy: an analysis of published studies. Clin Exp Allergy (2005) 1.69

Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol (2005) 1.68

Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System. J Allergy Clin Immunol (2010) 1.67

Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest (1993) 1.66

Tregs and allergic disease. J Clin Invest (2004) 1.64

Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. J Allergy Clin Immunol (2007) 1.64

Grass pollen immunotherapy inhibits seasonal increases in basophils and eosinophils in the nasal epithelium. Clin Exp Allergy (2001) 1.61

IgE antibody measurements in ragweed hay fever. Relationship to clinical severity and the results of immunotherapy. J Clin Invest (1973) 1.58

Increased risk for anaphylactoid reaction from contrast media in patients on beta-adrenergic blockers or with asthma. Ann Intern Med (1991) 1.58

Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy (2001) 1.56

Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol (2010) 1.55

Mechanisms of immunotherapy. J Allergy Clin Immunol (2004) 1.45

Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol (2006) 1.41

Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy (2006) 1.40

Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J Allergy Clin Immunol (2008) 1.38

Immunotherapy decreases antigen-induced eosinophil cell migration into the nasal cavity. J Allergy Clin Immunol (1991) 1.37

Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol (2002) 1.34

Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol (1997) 1.27

Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann Allergy Asthma Immunol (2006) 1.26

Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol (2006) 1.26

Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev (2003) 1.23

Efficacy and safety of preseasonal-specific immunotherapy with an aluminium-adsorbed six-grass pollen allergoid. Allergy (2005) 1.22

Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects. Eur J Immunol (1997) 1.22

Increased expression of allergen-induced in vitro interleukin-10 and interleukin-18 mRNA in peripheral blood mononuclear cells of allergic rhinitis patients after specific immunotherapy. Clin Exp Allergy (2004) 1.19

Survey of fatalities from skin testing and immunotherapy 1985-1989. J Allergy Clin Immunol (1993) 1.17

Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol (1996) 1.16

Systemic reactions and fatalities associated with allergen immunotherapy. Ann Allergy Asthma Immunol (2001) 1.16

Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children. Allergy (2006) 1.15

The effect of immunotherapy on bronchial hyperresponsiveness and eosinophil cationic protein in pollen-allergic patients. J Allergy Clin Immunol (1988) 1.15

Grass pollen immunotherapy induces an allergen-specific IgA2 antibody response associated with mucosal TGF-beta expression. J Immunol (2007) 1.12

Evaluation of near-fatal reactions to allergen immunotherapy injections. J Allergy Clin Immunol (2006) 1.11

The effect of immunotherapy on humoral and cellular responses in ragweed hayfever. J Clin Invest (1976) 1.09

Anaphylaxis to multiple pollen allergen sublingual immunotherapy. Allergy (2007) 1.08

Anaphylactic reaction after the first dose of sublingual immunotherapy with grass pollen tablet. Allergy (2009) 1.08

Sublingual immunotherapy with Dermatophagoides monomeric allergoid down-regulates allergen-specific immunoglobulin E and increases both interferon-gamma- and interleukin-10-production. Clin Exp Allergy (2006) 1.06

The IgE-facilitated allergen binding (FAB) assay: validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses. J Immunol Methods (2006) 1.03

Sub-lingual immunotherapy: world allergy organization position paper 2009. World Allergy Organ J (2009) 1.03

Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE. J Allergy Clin Immunol (2012) 1.03

Effects of sublingual immunotherapy for multiple or single allergens in polysensitized patients. Ann Allergy Asthma Immunol (2007) 0.98

Efficacy of sublingual allergen vaccination for respiratory allergy in children. Conclusions from one meta-analysis. J Investig Allergol Clin Immunol (2005) 0.97

Anaphylactic shock because of sublingual immunotherapy overdose during third year of maintenance dose. Allergy (2007) 0.96

Anaphylaxis to sublingual immunotherapy. Allergy (2006) 0.95

Studies on allergoids from naturally occurring allergens. IV. Efficacy and safety of long-term allergoid treatment of ragweed hay fever. J Allergy Clin Immunol (1981) 0.95

Specific immunotherapy in asthma. J Allergy Clin Immunol (1990) 0.93

Mechanisms of sublingual immunotherapy. J Asthma (2009) 0.93

Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy. J Allergy Clin Immunol (2012) 0.93

Update on immune mechanisms associated with sublingual immunotherapy: practical implications for the clinician. J Allergy Clin Immunol Pract (2013) 0.93

Interleukin-10, T regulatory cells and specific allergy treatment. Clin Exp Allergy (2004) 0.92

Desensitising vaccines: an allergist's view. Br Med J (Clin Res Ed) (1986) 0.92

Position paper: Immunotherapy. Allergy (1993) 0.92

Comparative study of cluster and conventional immunotherapy schedules with dermatophagoides pteronyssinus in the treatment of persistent allergic rhinitis. Int Arch Allergy Immunol (2008) 0.91

2006 American Academy of Allergy, Asthma & Immunology member immunotherapy practice patterns and concerns. J Allergy Clin Immunol (2007) 0.89

Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study. Allergy (2009) 0.89

Safety of specific sublingual immunotherapy with SQ standardized grass allergen tablets in children. Pediatr Allergy Immunol (2007) 0.88

Increase of regulatory T cells and the ratio of specific IgE to total IgE are candidates for response monitoring or prognostic biomarkers in 2-year sublingual immunotherapy (SLIT) for Japanese cedar pollinosis. Clin Immunol (2011) 0.87

Nonfatal systemic allergic reactions induced by skin testing and immunotherapy. Ann Allergy (1993) 0.87

The induced regulatory T cell level, defined as the proportion of IL-10(+)Foxp3(+) cells among CD25(+)CD4(+) leukocytes, is a potential therapeutic biomarker for sublingual immunotherapy: a preliminary report. Int Arch Allergy Immunol (2010) 0.86

Immunotherapy: a one-year prospective study to evaluate risk factors of systemic reactions. J Allergy Clin Immunol (1995) 0.86

Effect of specific immunotherapy added to pharmacologic treatment and allergen avoidance in asthmatic patients allergic to house dust mite. J Allergy Clin Immunol (2004) 0.85

Induction of interleukin 10 by sublingual immunotherapy for house dust mites: a preliminary report. Ann Allergy Asthma Immunol (2005) 0.85

Immunotherapy in asthma: an updated systematic review. Allergy (1999) 0.85

A three-year prospective study of specific immunotherapy to inhalant allergens: evidence of safety and efficacy in 300 children with allergic asthma. J Investig Allergol Clin Immunol (1997) 0.83

Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. V. Duration of the efficacy of immunotherapy after its cessation. Allergy (1996) 0.83

Safety and tolerability of seasonal ultra-rush, high-dose sublingual-swallow immunotherapy in allergic rhinitis to grass and tree pollens: an observational study in 193 children and adolescents. J Investig Allergol Clin Immunol (2009) 0.83

Preseasonal local allergoid immunotherapy to grass pollen in children: a double-blind, placebo-controlled, randomized trial. Allergy (2000) 0.83

Double-blind trial of house-dust mite immunotherapy in asthmatic children resident at high altitude. Allergy (1995) 0.82

Impact of sublingual immunotherapy on specific antibody levels in asthmatic children allergic to house dust mites. Int Arch Allergy Immunol (2005) 0.82

Immunological responses to allergen immunotherapy. Clin Allergy Immunol (2004) 0.81

Allergen immunotherapy safety: characterizing systemic reactions and identifying risk factors. Allergy Asthma Proc (2008) 0.81

Grass allergen tablet immunotherapy relieves individual seasonal eye and nasal symptoms, including nasal blockage. Allergy (2007) 0.80

Sublingual immunotherapy in children modulates allergen-induced in vitro expression of cytokine mRNA in PBMC. Allergy (2006) 0.80

Oral immunotherapy of children with rhinoconjunctivitis due to birch pollen allergy. A double blind study. Allergy (1986) 0.80

Antihistamine premedication in specific cluster immunotherapy: a double-blind, placebo-controlled study. J Allergy Clin Immunol (1996) 0.80

Sublingual allergen immunotherapy: immunological mechanisms and prospects for refined vaccine preparation. Curr Med Chem (2007) 0.79

Management of rhinitis and asthma in pregnancy. Ann Allergy Asthma Immunol (2003) 0.78

Specific IgE response before and after rush immunotherapy with a standardized allergen or allergoid in grass pollen allergy. Ann Allergy (1986) 0.78

Anaphylaxis caused by allergen sublingual immunotherapy? Allergy (2007) 0.78

The safety of sublingual immunotherapy with one or more allergens in adults. Allergy (2008) 0.77

The "physician on call patient engagement trial" (POPET): measuring the impact of a mobile patient engagement application on health outcomes and quality of life in allergic rhinitis and asthma patients. Int Forum Allergy Rhinol (2015) 0.81

Efficacy of sublingual immunotherapy for house dust mite allergic rhinitis. Eur Arch Otorhinolaryngol (2014) 0.78

The possible mechanisms of the human microbiome in allergic diseases. Eur Arch Otorhinolaryngol (2016) 0.75